nanotech investing Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update
nanotech investing Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults
nanotech investing Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
nanotech investing Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte's 31-Valent Pneumococcal Conjugate Vaccine Candidate
nanotech investing Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
nanotech investing Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines
nanotech investing Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026
nanotech investing Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
nanotech investing Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
Skull Ridge Gold Acquires 17,225-Hectare Strategic Land Position Along Emerging Crippleback–Stony Lake Gold-Copper Corridor
Jaguar Uranium Reports Final Copper Assay Results Including up to 8.54% Copper, Potential 4-km Trend Identified from Huemul Uranium-Copper-Vanadium Project
